Physician profile
Nathaniel Sumilang
NPI 1932192754
$3,547.68
in general payments reported to CMS, 2019-2025
28 companies · $467 in 2025
The $467 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $457 · 2021: $586 · 2022: $499 · 2023: $612 · 2024: $466 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $455.22 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $452.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $393.45 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $359.91 | 2019-2023 | Trintellix |
| Tris Pharma INC | $275.23 | 2020-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $197.54 | 2021-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $181.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $178.83 | 2021-2024 | Bexsero |
| Collegium Pharmaceutical, INC. | $153.41 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $115.08 | 2020-2021 | |
| Amgen INC. | $104.68 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $104.05 | 2020-2025 | Rybelsus, Ozempic |
| Seqirus USA INC | $74.67 | 2021-2025 | Flucelvax, Fluad |
| Shire North American Group INC | $69.49 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $59.35 | 2023 | Flumist Quadrivalent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.13 | 2025 | |
| Adlon Therapeutics L.P. | $52.61 | 2020-2021 | |
| Cranial Technologies, INC | $41.71 | 2019 | |
| Exact Sciences Corporation | $34.47 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $28.81 | 2021-2025 | Zoryve |
| Abbvie INC. | $28.25 | 2025 | |
| Neos Therapeutics, Lp | $23.89 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.67 | 2023 | |
| Arbor Pharmaceuticals, INC. | $21.54 | 2019 | |
| Medtronic, INC. | $17.82 | 2025 | Closurefast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2020 | |
| Medtronic Vascular, INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Sumilang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.